


# Financial Factsheet

## H1 2025


01.10.2024-31.03.2025

### GROUP


#### Revenue-Bridge (EURm)



#### Revenues by region (EURm)



#### Revenues by segment (EURm)



#### Results (EURm)

	H1 2025	H1 2024
Revenues	482	466
EBITDA	130	117
EBITDA margin	26.9%	25.1%
EBITDA margin (at constant currencies)	27.3%	27.4%
EBIT	92	87
EBIT margin	19.1%	18.5%
Financial result	-6	-4
Income tax expense	-18	-12
Profit for the period	68	70
EPS (in EUR)	0.45	0.46

#### Financial position (EURm)

	H1 2025	H1 2024
Cash flow from operating activities (A)	72	91
Cash flow from investing activities (B)	-50	-57
Free cash flow (A+B)	22	34

#### Net assets (EURm)

	31.3.2025	30.9.2024
Working Capital	204	175
Working Capital ratio to revenues	21.0%	18.3%
Equity ratio	56.5%	54.9%
Net debt	126	119


#### Employees

	31.3.2025	30.9.2024
Headcount	4,790	4,690

### DRUG CONTAINMENT SOLUTIONS

(DCS)\*

#### Revenue-Bridge (EURm)




#### Results (EURm)

	H1 2025	H1 2024
EBITDA	62	54
EBITDA margin	22.6%	20.7%
EBIT	43	37
EBIT margin	15.9%	14.3%

### DRUG DELIVERY SYSTEM

(DDS)\*

#### Revenue-Bridge (EURm)



#### Results (EURm)

	H1 2025	H1 2024
EBITDA	72	78
EBITDA margin	34.1%	38.3%
EBIT	53	65
EBIT margin	25.1%	31.9%